Vacchi-Suzzi Martino, Bocciolini Corso, Bertarelli Claudia, Dall'Olio Danilo
Department of Otolaryngology-Head and Neck Surgery, Maggiore Hospital, Bologna, Italy.
Ann Otol Rhinol Laryngol. 2010 Oct;119(10):677-83. doi: 10.1177/000348941011901006.
The study was performed to evaluate the prognostic relevance of cell proliferation associated with Ki-67/ Mib-1 immunostaining in malignant tumors of the major salivary glands.
Cell proliferation was evaluated by Mib-1 antibody against Ki-67 antigen in 41 patients with cancer of the parotid or submandibular glands, including 14 acinic cell carcinomas, 12 ductal carcinomas, 7 mucoepidermoid carcinomas, 5 carcinomas ex pleomorphic adenoma, 1 adenoid cystic carcinoma, 1 undifferentiated carcinoma, and 1 polymorphous low-grade adenocarcinoma.
Patients with Ki-67 values of more than 15% and those with Ki-67 values of 15% or less differed both in disease-free survival (p < 0.001) and in overall survival (p < 0.001). We evaluated the association between Ki-67 and time to recurrence in correlation to age, sex, ductal histotype, and N stage; the Cox regression model was significant (p = 0.013). In the group of patients with T1 and T2 cancers, those with Ki-67 values of 15% or less had better survival rates than did those with Ki-67 values of more than 15% (p = 0.004). In the group of patients with N0 cancers, those with Ki-67 values of 15% or less had a better survival than did those with Ki-67 values of more than 15% (p < 0.001).
To our knowledge, this is the first study to stratify different risk classes in early T1-T2 or N0 malignant tumors of the major salivary glands that identified aggressive lesions with elevated Ki-67 expression at an initial stage.
本研究旨在评估与Ki-67/Mib-1免疫染色相关的细胞增殖在大唾液腺恶性肿瘤中的预后相关性。
采用抗Ki-67抗原的Mib-1抗体对41例腮腺或颌下腺癌患者的细胞增殖情况进行评估,其中包括14例腺泡细胞癌、12例导管癌、7例黏液表皮样癌、5例多形性腺瘤癌变、1例腺样囊性癌、1例未分化癌和1例多形性低度腺癌。
Ki-67值大于15%的患者与Ki-67值小于或等于15%的患者在无病生存期(p < 0.001)和总生存期(p < 0.001)方面均存在差异。我们评估了Ki-67与复发时间之间的关联,并与年龄、性别、导管组织学类型和N分期进行相关性分析;Cox回归模型具有显著性(p = 0.013)。在T1和T2期癌症患者组中,Ki-67值小于或等于15%的患者生存率高于Ki-67值大于15%的患者(p = 0.004)。在N0期癌症患者组中,Ki-67值小于或等于15%的患者生存率高于Ki-67值大于15%的患者(p < 0.001)。
据我们所知,这是第一项对大唾液腺早期T1-T2或N0期恶性肿瘤进行不同风险分层的研究,该研究在初始阶段识别出具有Ki-67表达升高的侵袭性病变。